Business Context and Reporting Period
Company: Novanta Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended July 3, 2026
Business Overview: Novanta is a global supplier of core technology solutions for medical and advanced industrial OEMs, operating through two segments: Automation Enabling Technologies and Medical Solutions.
Key Financial Metrics (Six Months Ended July 3, 2026)
| Metric | Value (in thousands) |
|---|---|
| Revenue | $523,514 |
| Gross Profit | $234,493 |
| Gross Margin | 44.8% |
| Operating Income | $45,600 |
| Net Income | $33,640 |
| Diluted EPS | $0.82 |
| Operating Cash Flow | $116,540 |
| Cash and Equivalents (End of Period) | $718,650 |
| Total Debt (End of Period) | $229,656 |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 10.3% year-over-year (YoY) to $523.5 million, driven by organic growth in both segments and $9.0 million in revenue from the 2025 acquisition of Keonn Technologies.
- Profitability: Operating income decreased 3.7% YoY to $45.6 million, primarily due to a $21.7 million increase in Selling, General, and Administrative (SG&A) expenses and a $5.0 million increase in restructuring and acquisition costs, which offset a $23.4 million increase in gross profit.
- Segment Performance:
- Automation Enabling Technologies: Revenue up 9.2%; Operating income up 16.1% to $67.7 million.
- Medical Solutions: Revenue up 11.5%; Operating income up 46.9% to $30.3 million.
- Capital Structure: The company completed a private placement of common shares in June 2026, raising net proceeds of approximately $287.6 million.
Guidance, Outlook, and Material Events
- Major Acquisition (Subsequent Event): On July 23, 2026, Novanta completed the acquisition of Riverpoint Medical for $1.2 billion in upfront cash consideration plus a potential $250 million milestone payment. This transaction significantly increased consolidated gross debt to approximately $854.8 million post-closing.
- Restructuring Programs: The company is executing 2024 and 2025 restructuring programs to streamline operations and regionalize manufacturing. Total expected costs for the 2025 program are approximately $30.0 million.
- Debt Covenants: The company amended its credit agreement to accommodate the Riverpoint acquisition, increasing the permitted consolidated leverage ratio to 4.00:1.00 (or 4.50:1.00 for four quarters post-acquisition). As of July 3, 2026, the actual leverage ratio was 0.57:1.00.
- Risks: Management highlights risks related to geopolitical conflicts (specifically US/Israel/Iran tensions affecting supply chains and energy costs), inflation, and the integration of the Riverpoint Medical acquisition.
Investor Verification Checklist
- Debt Capacity: Verify the impact of the $1.2 billion Riverpoint Medical acquisition on future leverage ratios and interest expense, noting the debt increased from ~$230 million to ~$855 million immediately post-closing.
- SG&A Efficiency: Investigate the drivers of the $21.7 million YoY increase in SG&A expenses, specifically costs related to financial/operational system implementation and variable compensation.
- Integration Synergies: Monitor the integration progress of Riverpoint Medical and Keonn Technologies to ensure anticipated revenue and margin synergies are realized.
- Supply Chain Resilience: Assess exposure to geopolitical risks and single-source suppliers, particularly regarding rare-earth materials from China and energy costs.
- Share Count: Confirm the dilutive impact of the private placement (2.14 million shares) and the 6.50% Tangible Equity Units on future earnings per share.